LLY Jan 2025 270.000 call
| Previous Close | 682.45 |
| Open | 682.45 |
| Bid | 651.00 |
| Ask | 659.80 |
| Strike | 270.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 682.45 - 682.45 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 177 |
Investor's Business DailyIs Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug?
The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now?
ZacksRVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.
ReutersUS Senator Warren calls for scrutiny of Novo Holdings' Catalent deal
NEW YORK (Reuters) -U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's controlling shareholder would acquire contract drug manufacturer Catalent, saying it may give the pharmaceutical company an unlawful advantage in obesity drugs. Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, signed a $16.5 billion deal to buy Catalent in February to boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight loss drug. Warren urged the U.S. Federal Trade Commission to sue to block the deal if the regulator finds it illegal – which could delay the deal's expected closing later this year.
